Prediction of Candidate Drugs for Treating Pancreatic Cancer by Using a Combined Approach.
Pancreatic cancer is the leading cause of death from solid malignancies worldwide. Currently, gemcitabine is the only drug approved for treating pancreatic cancer. Developing new therapeutic drugs for this disease is, therefore, an urgent need. The C-Map project has provided a wealth of gene express...
Main Authors: | Yanfen Ma, Jian Hu, Ning Zhang, Xinran Dong, Ying Li, Bo Yang, Weidong Tian, Xiaoqin Wang |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2016-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC4765895?pdf=render |
Similar Items
-
Effects of repurposed drug candidates nitroxoline and nelfinavir as single agents or in combination with erlotinib in pancreatic cancer cells
by: Serena Veschi, et al.
Published: (2018-09-01) -
Identification of Candidate Biomarker ASXL2 and Its Predictive Value in Pancreatic Carcinoma
by: Gaoming Wang, et al.
Published: (2021-10-01) -
Identification of a potent benzoxaborole drug candidate for treating cryptosporidiosis
by: Christopher S. Lunde, et al.
Published: (2019-06-01) -
Novel candidate factors predicting the effect of S-1 adjuvant chemotherapy of pancreatic cancer
by: Katsutaka Mitachi, et al.
Published: (2021-03-01) -
Development of a new system for screening potential drug candidates to treat fasciolosis
by: Moore, C. M.
Published: (2013)